==================================================
Internet Stock Review Online, Tuesday 09/17/2002.
Los Angeles 61...78F Sunny.
==================================================
Table Of Contents:
1. Supergen. (SUPG) $3.00
2. Three New Idea Coming.
3. Disclaimer
==================================================
SuperGen Receives Orphan Drug Status.
Supergen, the most recent addition to the Biotech Stock Review at $2.69,
announced getting Orphan Drug status on Decitabine today. We originally
liked SUPG for a trade, because the company had the cohones to say in a
press release that the weakness in the the stock price was attributable to
a "margin call" by Chairman. It is now looking more like an "investment."
"Investments" are speculative stocks that work out, "speculative stocks"
are investments that don't. SUPG has about $49 million in cash.
tinyurl.com
Traded as high as $3.57 this morning.
==================================================
DUBLIN, Calif., Sept. 17 /PRNewswire-FirstCall/ -- SuperGen, Inc. (Nasdaq:
SUPG) announced today that decitabine has received orphan-drug designation
from the Food and Drug Administration (FDA) for the treatment of sickle
cell anemia.
biz.yahoo.com
Orphan drug status promotes development of drugs to treat rare diseases or
conditions by protecting them from competition for certain periods from
other medicines in the same class of drugs.
The designation is granted for treatments that may offer significant
benefit in patients with serious or life-threatening diseases that occur
in not more than 200,000 patients. SuperGen's drug has already been
granted orphan drug status for another use.
Reuters reported its experimental treatment for sickle cell anemia could
receive up to seven years of marketing exclusivity under a special
designation granted by U.S. regulators.
Dow Jones reported in addition to potential market exclusivity, orphan
drug status provides tax incentives for up to 50% of a company's
investment in U.S. clinical research, available funding to support
clinical trials, and study design assistance.
=================================================
New Ideas Coming.
We are looking at 3 new ideas.
Two in healthcare, one in Hollywood.
One has a revolutionary chain of pharamacies, linked to Doctor's via a
handheld device. (Biotech Stock Review)
One claims the ability to cure alcohol and drug dependence. (Biotech Stock
Review)
One believes it can earn $0.17 next year and has a price under $0.17.
(Hollywood Stock Review)
SURELY....one of these ideas can make us rich again, right ?
Stay tuned, if nothing else, we're going to have a lot of fun with these
companies.
To Subscribe: join-internetstockreview@sparklist.com
==================================================
---
You are currently subscribed to internetstockreview as: yourassismine@fukyou.com
To unsubscribe send a blank email to leave-internetstockreview-6097355K@laser.sparklist.com |
